Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) by Giebel, Sebastian et al.
ORIGINAL ARTICLE
Trends in the use of hematopoietic stem cell transplantation
for adults with acute lymphoblastic leukemia in Europe: a report
from the Acute Leukemia Working Party of the European Society
for Blood and Marrow Transplantation (EBMT)
Sebastian Giebel1 & Ariane Boumendil2,3 & Myriam Labopin2,3 & Anouchka Seesaghur4 & Frederic Baron5 &
Fabio Ciceri6 & Jordi Esteve7 & Norbert-Claude Gorin2,3 & Bipin Savani8 & Christoph Schmid9 & Sally Wetten4 &
Mohamad Mohty2 & Arnon Nagler3,10
Received: 18 January 2019 /Accepted: 29 July 2019 /Published online: 7 August 2019
# The Author(s) 2019
Abstract
Hematopoietic stem cell transplantation (HSCT) is considered an effective way to prevent relapse in adults with acute lympho-
blastic leukemia (ALL). This study aimed to assess general trends in the use of various types of HSCTs performed between 2001
and 2015 in Europe, based on data reported to the European Society for Blood and Marrow Transplantation registry. We also
evaluated HSCT rates with respect to ALL incidence in selected countries. Altogether, 15,346 first allogeneic (n = 13,460) or
autologous (n = 1886) HSCTs were performed in the study period. Comparing 2013–2015 and 2001–2003, the number of
allogeneic HSCTs performed in first complete remission increased by 136%, most prominently for transplantations from unre-
lated (272%) and mismatched related donors (339%). The number of HSCTs from matched sibling donors increased by 42%,
while the total number of autologous HSCTs decreased by 70%. Increased use of allogeneic HSCTwas stronger for Philadelphia
chromosome (Ph)-positive (166%) than for Ph-negative ALL (38%) and for patients aged > 55 years (599%) than for younger
adults (59%). The proportion of allogeneic HSCTwith reduced-intensity conditioning (RIC) increased from 6 to 27%. The age-
standardized rates of allogeneic HSCT per ALL incidence varied strongly among countries. Our analysis showed a continued
trend toward increased allogeneic HSCT use for adults with ALL, which may be attributed to increasing availability of unrelated
donors, wider use of RIC regimens, and improving efficacy of pretransplant therapy, including tyrosine kinase inhibitors for Ph-
positive ALL. Allogeneic HSCT remains a major tool in the fight against ALL in adults.
Initial results of the study were reported as oral presentation during the
21st Congress of the European Hematology Association in Copenhagen
(2016).
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Introduction
Acute lymphoblastic leukemia (ALL) is one of the most ag-
gressive malignancies. It is usually sensitive to multi-agent
chemotherapy, which allows the initial achievement of com-
plete remission (CR) in the majority of cases [1]. Nonetheless,
approximately half of the patients achieving initial CR will
relapse, which is associated with a very poor prognosis [2].
Allogeneic hematopoietic stem cell transplantation (HSCT) is
considered an effective way to prevent relapse. It offers a
chance to use myeloablative doses of chemotherapy and/or
radiotherapy and may be associated with the beneficial graft-
versus-leukemia reaction mediated by T cells of donor origin.
The efficacy of allogeneic HSCTwas confirmed in prospec-
tive trials conducted in the 1990s, comparing long-term outcome
in subgroups defined based on the availability of human leuko-
cyte antigen (HLA)-matched sibling donor (MSD) [3, 4]. In the
twenty-first century, with a growing number of registered volun-
teers, a chance of finding an HLA-compatible unrelated donor
(URD) increased markedly [5]. Finally, novel immunosuppres-
sive protocols have been elaborated, allowing for transplantations
from partially mismatched related donors (MMRDs), namely
haploidentical donors [6].
Unfortunately, HSCT is associated with a significant risk of
life-threatening complications, among which infections and
graft-versus-host disease are the most frequent causes of death.
Despite improvement observed over time, the estimated risk of
nonrelapse mortality remains 15% for HSCTs from MSDs and
22% for HSCTs fromURDs [7]. Therefore, many national study
groups attempt to reduce the indications for HSCT in favor of
more intensive conventional dose chemotherapy. A strict evalu-
ation of response based on minimal residual disease (MRD)
assessment allows for a more precise identification of patients
at lower risk of relapse. Furthermore, new and more active ther-
apeutic options have been developed and introduced into clinical
practice in advanced disease, including immunotoxins, bispecific
T cell enhancers, and chimeric antigen receptor T cells [8–11].
For ALL with the presence of t(9;22), called Philadelphia chro-
mosome (Ph), new generations of tyrosine kinase inhibitors
(TKIs) with strong anti-ABL activity became available, offering
highly effective ways of targeted therapy [12].
Taken together, the role of HSCT in the treatment of adults
with ALL is a subject of debate. The goal of the current study
was to analyze trends in the use of HSCT for adults with ALL in
Europe. Data were analyzed as absolute number of procedures
performed in subsequent time periods and relative to ALL inci-
dence in selected countries. Finally, we looked at associations
between the use of HSCT and socioeconomic factors.
Methods
This is a retrospective registry-based analysis on behalf of the
Acute Leukemia Working Party (ALWP) of the European
Society for Blood and Marrow Transplantation (EBMT).
The EBMT is a voluntary working group of more than 500
transplant centers that are required to report all consecutive
HSCTs and follow-ups once a year. The validation and quality
control program includes the verification of computer print-
outs of the entered data, cross-checking with the national reg-
istries, and on-site visits of selected teams.
All allogeneic or autologous HSCTs performed in adult
patients (≥ 18 years old) with ALL, between 2001 and 2015,
were included in the analysis. The number of procedures was
reported in subsequent 3-year intervals (2001–2003, 2004–
2006, 2007–2009, 2010–2012, and 2013–2015). The analysis
included donor type, disease stage at transplantation, ALL
subtypes, recipient age, type and intensity of conditioning
regimen, and the source of hematopoietic stem cells.
For the selected 11 countries (Denmark, Finland, France,
Germany, Italy, Netherlands, Norway, Poland, Russia, Spain,
and Sweden), age-standardized rates (per 100 diagnosed ALL
cases) of allogeneic HSCT performed in first CRwere calculated
from2001 to 2015 for each country inwhichALL incidence data
were available. ALL diagnosis incidence data were based on
publicly available data reported by country-specific population-
based cancer registries. This part of the analysis was restricted to
patients aged 20 years or more. Allogeneic HSCT rates for the
period 2013–2015 were further correlated with the Human
Development Index (HDI) and gross domestic product (GDP)
per capita. The values of HDI and GDP were obtained from the
2015 Human Development Report, published by the United
Nations [13], referring to data from 2014 and 2013. Spearman
test was used to evaluate the associations.
Results
HSCT numbers according to donor type and disease
stage
Between 2001 and 2015, 15,346 first HSCT procedures
were performed in 32 European countries, including
13,460 allogeneic and 1886 first autologous transplanta-
tions. Among allogeneic HSCTs, URDs were used in
6953 cases (52%), followed by MSDs (n = 5740; 43%)
and MMRDs (n = 767; 6%). A continued increase in the
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total number of allogeneic HSCTs was observed over
time, mostly in patients in first CR (Table 1; Fig. 1).
Comparing 2013–2015 and 2001–2003, the number of
allogeneic HSCTs performed in first CR increased by
136%, most prominently for transplantations from URDs
(272%) and MMRDs (339%). In respective periods, the
number of HSCTs from MSDs increased by 42%. The
number of allogeneic HSCTs for patients treated in second
or subsequent CR was stable over time except for
MMRD-HSCT, where an increase of 416% was observed.
In contrast, the use of autologous HSCTs decreased over
time, starting from 707 procedures performed in 2001–
2003 to 211 procedures registered in 2013–2015.
Altogether, the proportion of allogeneic HSCTs ana-
lyzed by donor type changed in favor of URD (41% ver-
sus 56% URD-HSCTs among all transplantations between
2001 and 2003 versus 2013 and 2015) and MMRD (5%
versus 10%).
HSCT numbers by disease subtype
Data regarding the presence of Ph status were available
for approximately 55% of the recipients of allogeneic
HSCT with B cell precursor ALL. In these patients, the
absolute number of allogeneic transplantations increased
over time for both Ph-negative and Ph-positive ALL;
however, the increase was more pronounced for Ph-
positive versus Ph-negative disease (166% versus 38%
from 2001–2003 to 2013–2015; Table 2). The proportion
of transplants for Ph-positive ALL among allogeneic
HSCT recipients with known karyotype increased from
31 to 40%. In parallel, the number of autologous HSCTs
decreased by 78% and 5% for Ph-negative and Ph-
positive ALL, respectively. Notably, between 2013 and
2015, patients with Ph-positive ALL constituted 47% of
autologous HSCT recipients compared with 17% between
2001 and 2003.
Table 1 Trends in the use of hematopoietic stem cell transplantation according to donor type and disease status
Donor type Disease stage at transplantation Years
2001–2003 2004–2006 2007–2009 2010–2012 2013–2015
Allogeneic Total, n 1890 2221 2754 3115 3480
CR1 1006 (55) 1347 (62) 1816 (67) 2108 (69) 2374 (70)
CR > 1 398 (22) 468 (22) 556 (20) 588 (19) 660 (19)
Relapsed/refractory 413 (23) 357 (16) 343 (13) 357 (12) 353 (10)
Unknown, n 73 49 39 62 93
Matched sibling Total, n 1019 1104 1197 1231 1189
CR1 606 (62) 737 (68) 823 (70) 867 (72) 860 (74)
CR > 1 161 (16) 192 (18) 215 (18) 206 (17) 183 (16)
Relapsed/refractory 214 (22) 150 (14) 141 (12) 130 (11) 113 (10)
Unknown, n 38 25 18 28 33
Unrelated Total, n 782 1036 1456 1726 1953
CR1 362 (48) 583 (57) 957 (67) 1169 (69) 1347 (71)
CR > 1 219 (29) 252 (25) 302 (21) 335 (20) 384 (24)
Relapsed/refractory 171 (23) 179 (18) 176 (12) 191 (11) 176 (10)
Unknown, n 30 22 21 31 46
Mismatched related Total, n 89 81 101 158 338
CR1 38 (45) 27 (34) 36 (36) 72 (46) 167 (52)
CR > 1 18 (21) 24 (30) 39 (39) 47 (30) 93 (29)
Relapsed/refractory 28 (33) 28 (35) 26 (26) 36 (23) 64 (20)
Unknown, n 5 2 0 3 14
Autologous Total, n 707 496 272 158 211
CR1 461 (70) 327 (69) 164 (61) 135 (72) 156 (80)
CR > 1 85 (13) 64 (14) 34 (13) 18 (10) 21 (11)
Relapsed/refractory 111 (17) 80 (17) 69 (26) 34 (18) 19 (10)
Unknown, n 50 25 5 13 15
Data are n (%) using non-missing data unless specified otherwise. Only first allogeneic or autologous transplantations were included in the analysis
CR complete remission; CR1 first CR, CR > 1 s or subsequent CR
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Data on immune subtype were available for 92% of the
patients treated with allogeneic HSCTand 93% of those treat-
ed with autologous HSCT. Similar trends were observed for
both B cell precursor and T cell precursor ALL (Table 2). The
number of allogeneic HSCTs was continuously increasing,
while the number of autologous HSCTs was decreasing over
time regardless of the immune subtype.
HSCT and age
Between 2001 and 2003, patients older than 55 years constituted
5% of all adults treated with allogeneic HSCT and 13% of those
treated with autologous HSCT, while between 2013 and 2015,
the proportions were 18% and 27%, respectively (Table 3). The
most prominent increase was observed for URD-HSCT (by
1415%) andMMRD-HSCT (by 2300%). The 55 years age limit
is most frequently used by the European ALL study groups to
define patients’ eligibility for intensive chemotherapy and
myeloablative transplant procedures [14].
Conditioning regimens and stem cell source
Several aspects of the transplantation procedure, including the
type of conditioning and source of hematopoietic stem cells,
were analyzed for patients treated with allogeneic HSCT in
first CR (Table 4). The proportion of transplantations with
reduced-intensity conditioning (RIC) increased from 6% in
2001–2003 to 26% in 2010–2012 [15]. Among myeloablative
regimens, the use of total body irradiation (TBI) was predom-
inant and stable over time, accounting for approximately 80%
of all procedures. In contrast, chemotherapy-based regimens
were more frequently used in the reduced-intensity setting,
and their proportion increased from 53% in 2001–2003 to
84% in 2013–2015.
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Fig. 1 Trends in the use of HSCT according to donor type and disease
stage at transplantation. a All allogeneic HSCT. bMatched sibling donor
HSCT. c Unrelated donor HSCT. d Mismatched related donor HSCT. e
Autologous HSCT. CR complete remission; CR1 first CR, CR > 1 s or
subsequent CR; HSCT hematopoietic stem cell transplantation
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Peripheral blood was the predominant source of stem
cells, accounting for 61% of the allogeneic HSCT proce-
dures in 2001–2003, with an increase up to 84% in 2013–
2015. In the most recent period, 16% of transplants were
performed using bone marrow as a source of stem cells
when compared to 38% in the period 2001–2003. Cord
blood use was limited to less than 1% throughout the 15-
year study period.
HSCT rates per ALL incidence
Age-standardized rates of first allogeneic HSCT per-
formed in first CR, calculated per 100 diagnosed ALL
incidence cases in patients aged 20 years and above, var-
ied substantially among the analyzed countries (Fig. 2).
The highest rates and most prominent increase in recent
period were observed in Finland, followed by the
Table 2 Trends in the use of hematopoietic stem cell transplantation according to disease subtype
Donor type Disease subtype Ph status Years
2001–
2003
2004–
2006
2007–
2009
2010–
2012
2013–
2015
Allogeneic Total, n 1890 2221 2754 3115 3480
Allogeneic B cell precursor Total 1211 (73) 1535 (73) 1959 (77) 2166 (75) 2502 (78)
Ph-negative 327 (27) 343 (22) 342 (17) 380 (17) 452 (18)
Ph-positive 377 (31) 417 (27) 729 (37) 812 (37) 1003 (40)
Unknown, n 507 775 888 974 1047
T cell precursor 403 (24) 539 (26) 591 (23) 704 (24) 720 (22)
Other 42 (3) 35 (2) 3 (0) 6 (0) 4 (0)
Unknown, n 234 112 201 239 254
Autologous Total, n 707 496 272 200 211
B cell precursor Total 381 (59) 259 (55) 165 (64) 110 (60) 127 (65)
Ph-negative 79 (21) 45 (17) 30 (18) 12 (11) 17 (13)
Ph-positive 63 (17) 37 (14) 50 (30) 44 (40) 60 (47)
Unknown, n 239 177 85 54 50
T cell precursor 247 (38) 206 (44) 94 (36) 74 (40) 66 (34)
Other 20 (3) 6 (1) 0 (0) 0 (0) 1 (1)
Unknown, n 59 25 13 16 17
Data are n (%) using non-missing data unless specified otherwise. Only first allogeneic or autologous transplantations were included in the analysis
Ph Philadelphia chromosome
Table 3 Trends in the use of
hematopoietic stem cell
transplantation according to
donor type and recipient age
category
Donor type Age (years) Years
2001–2003 2004–2006 2007–2009 2010–2012 2013–2015
Total allogeneic 18–55 1801 (95) 2069 (93) 2428 (88) 2679 (86) 2858 (82)
> 55 89 (5) 152 (7) 326 (12) 436 (14) 622 (18)
Matched sibling 18–55 958 (94) 1027 (93) 1054 (88) 1085 (88) 1009 (85)
> 55 61 (6) 77 (7) 143 (12) 146 (12) 180 (15)
Unrelated 18–55 756 (97) 961 (93) 1280 (88) 1452 (84) 1559 (80)
> 55 26 (3) 75 (7) 176 (12) 274 (16) 394 (20)
Mismatched related 18–55 87 (98) 81 (100) 94 (93) 142 (90) 290 (86)
> 55 2 (2) 0 (0) 7 (7) 16 (10) 48 (14)
Autologous 18–55 614 (87) 420 (85) 211 (78) 146 (73) 153 (73)
> 55 93 (13) 76 (15) 61 (22) 54 (27) 58 (27)
Data are n (%). Only first allogeneic or autologous transplantations were included in the analysis
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Netherlands and Sweden; the lowest rates were noted in
Russia. In several countries, including Germany and
Poland, a marked increase was observed between 2007
and 2009 compared with the preceding periods, followed
by a plateau in 2010–2015.
No statistically significant associations could be dem-
onstrated for HSCT rates with either HDI (Spearman cor-
relation = 0.21; p = 0.54) or GDP per capita (Spearman
correlation = − 0.08; p = 0.81).
Discussion
This comprehensive analysis on the activity of transplantation
for ALL showed a marked increase in the number of alloge-
neic HSCTs performed during a 15-year period (2001–2015),
especially in first CR, as a consolidation strategy aimed to
decrease relapse risk. This increased transplant activity was
based on diverse reasons, such as (a) the use of highly effec-
tive TKIs in Ph-positive ALL, resulting in a significantly high
Table 4 Type of conditioning and stem cell sources for allogeneic hematopoietic stem cell transplantation in first complete remission
Years
2001–2003 2004–2006 2007–2009 2010–2012 2013–2015
Intensity of conditioning Total, n 1006 1347 1816 2108 2374
Myeloablative 901 (94) 1184 (89) 1537 (86) 1678 (81) 1689 (73)
Reduced 60 (6) 146 (11) 256 (14) 394 (19) 625 (27)
Unknown, n 45 17 23 36 60
Myeloablative conditioning Total, n 901 1184 1537 1678 1689
Chemotherapy based 118 (13) 166 (14) 272 (18) 313 (19) 393 (23)
TBI based 783 (87) 1015 (86) 1263 (82) 1365 (81) 1294 (77)
Unknown, n 0 3 2 0 2
Reduced-intensity conditioning Total, n 60 146 256 394 625
Chemotherapy based 32 (53) 89 (63) 182 (71) 311 (79) 525 (84)
TBI based 28 (47) 53 (37) 74 (29) 83 (21) 99 (16)
Unknown, n 0 4 0 0 1
Stem cell source Total, n 1006 1347 1816 2108 2374
Bone marrow 385 (38) 415 (31) 410 (23) 448 (21) 372 (16)
Peripheral blood 616 (61) 926 (69) 1401 (77) 1652 (78) 1994 (84)
Cord blood 3 (0) 6 (0) 4 (0) 4 (0) 4 (0)
Unknown, n 2 0 1 4 5
Data are n (%) using non-missing data unless specified otherwise
TBI total body irradiation
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proportion of patients achieving a major response that allowed
bridging to allogeneic HSCT; (b) the wider availability of
unrelated donors that currently constitute the main donor
source; and (c) the increased utility of RIC allogeneic HSCT,
which expands the potential benefit of transplantation to the
older ALL population.
Modern therapeutic protocols differ substantially for pa-
tients with Ph-positive and Ph-negative ALL. The presence
of t(9;22) was traditionally considered a very-high-risk
feature—associated with a lower chance of achieving CR
and a very high probability of relapse [16]. Allogeneic
HSCT provided the only reasonable chance of cure. The situ-
ation changed with the introduction of TKIs, which became
widely available in the middle of the last decade. As demon-
strated by studies comparing combined imatinib + chemother-
apy with historical controls using chemotherapy alone, CR
rates increased, followed by prolonged relapse-free survival
[17]. However, without allogeneic HSCT, a majority of the
patients ultimately relapse [18]. According to a study by
Chalandon et al., allogeneic HSCT is still associated with
significant benefit in terms of the overall survival in adults
with Ph-positive ALL, treated initially with the combination
of imatinib and reduced-dose chemotherapy [19]. The out-
come may further be improved when TKIs are used as
posttransplant maintenance [20]. Results of our retrospective
database analysis indicate that the number of allogeneic
HSCTs in first CR almost tripled for Ph-positive ALL within
the 15-year period. Clearly, the addition of imatinib to stan-
dard clinical practice improved the quality of response and
reduced the risk of early relapse, therefore increasing the
chance for patients to be treated with transplantation. In par-
allel, increasing availability of unrelated donors allowed for
identification of HLA-compatible donors for the majority of
patients in most European countries. More recently, the imple-
mentation of highly efficacious protocols of immunosuppres-
sion, such as the use of cyclophosphamide early after trans-
plantation from haploidentical donors, offers the availability
of a potential adequate donor to almost all patients in need of
allogeneic HSCT. Hence, it may be anticipated that the num-
ber of transplants for adults with Ph-positive ALL will further
increase. On the other hand, there are attempts to improve
results of conventional-dose treatment regimens by adding
second-generation (dasatinib, nilotinib) or third-generation
(ponatinib) TKIs to first-line treatment. In a study by the
European Working Group for Adult ALL, dasatinib in com-
bination with chemotherapy was offered to patients older than
55 years, who are usually not candidates for myeloablative
HSCT [21]. Despite a 65% rate of major molecular responses,
most patients relapsed within 5 years, leading to an overall
survival probability of 35%. Jabbour et al. reported the use
of ponatinib in combination with intensive chemotherapy for
younger adults with Ph-positive ALL [22]. The 2-year proba-
bility of event-free survival was 81%, although allogeneic
HSCT was offered to only nine out of 37 patients. It must be
stressed, however, that the follow-up of the study was relative-
ly short, while long-term safety of ponatinib remains a matter
of concern. Finally, with increasing efficacy of first-line treat-
ment, it appeared that autologous HSCT followed by TKI
maintenance may be a valuable alternative to allogeneic
HSCT, especially for patients achieving molecular remission
[23, 24]. According to our current study, the use of autologous
HSCT for patients with Ph-positive ALL was low and rather
stable over time; however, we speculate that some increase
may be anticipated in the future.
In contrast to Ph-positive ALL, treatment algorithms for
adults with Ph-negative disease are still based mainly on che-
motherapy. In recent years, the chemotherapy protocols have
been intensified following the pediatric experience in younger
adults. The indications for allogeneic HSCTare usually based
on risk stratification, with special attention put on the evalua-
tion of response at the level of MRD. According to results of a
study conducted by a French group using a pediatric-inspired
protocol, patients who achieve anMRD level below 10−3 after
induction chemotherapy do not necessarily benefit from allo-
geneic HSCT, regardless of the presence of conventional high-
risk features [25]. Results of our study demonstrated a trend
toward an increasing number of allogeneic HSCTs, although
much less pronounced compared with Ph-positive ALL.
Therefore, it may be speculated that the increasing availability
of donors may be partially counterbalanced by restricted indi-
cations for HSCT in patients achievingMRD negativity. In the
future, wide introduction of novel humoral and cellular immu-
notherapeutic approaches may change the landscape. The use
of rituximab in first-line treatment has already been demon-
strated to increase the probability of leukemia-free survival of
patients with CD20-positive ALL [26]. Drugs like
blinatumomab or inotuzumab ozogamicin are highly effective
in the relapsed/refractory B cell precursor ALL setting and
may serve as a bridge, enabling successful allogeneic HSCT
[8, 9]. On the other hand, when used frontline, they may in-
crease the chance of MRD eradication, further limiting the
role of transplant procedures.
ALL in elderly patients is associated with very poor prog-
nosis due to the high risk of chemotherapy-related complica-
tions, hence the need for dose intensity reduction [27]. These
patients are usually not candidates for transplantations with
myeloablative preparative regimens. In late 1990s, RIC regi-
mens were developed and introduced, allowing for wider ap-
plication of allogeneic HSCT to older patients, including those
with ALL [28]. This is reflected in the results of our study
showing a seven-fold increase in the total number of alloge-
neic HSCTand 15-fold increase in the number of URD-HSCT
for patients aged above 55 years. In similar proportions, the
number of reported RIC procedures increased over time.
Following general demographical trends toward increasing
life expectancy, it may be anticipated that the number of older
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patients in need for allogeneic HSCT, and consequently, the
number of procedures, will further grow in the future.
Numerous retrospective studies, including the recent analysis
by our group [7], indicate that myeloablative TBI-based prepar-
ative regimens are more effective than chemotherapy-based con-
ditioning, resulting in decreased risk of relapse and improved
leukemia-free survival. Results of the current study confirm the
predominant role of TBI in myeloablative setting, which was
stable over time. It may be speculated, however, that with the
development of new reduced-toxicity chemotherapy-based pro-
tocols, the landscape may change in the future. Encouraging
results have already been reported for preparative regimens using
thiotepa as a backbone [29]. Peripheral blood was the predomi-
nant source of stem cells over the entire study period showing a
continuous increase over time. This phenomenon has been al-
ready reported for allogeneic HSCT in other indications [30].
Allogeneic HSCT is considered one of the most expensive
medical procedures. The costs of URD-HSCT, most frequent-
ly used for patients with ALL, are particularly high and were
calculated as US dollars (USD) 161,000 in Sweden and USD
152,000 in the Netherlands [31, 32]. According to the analysis
by Stranges et al., HSCTs were procedures with the most
rapidly increasing costs of hospital stay in the USA between
2004 and 2007 [33]. The use of HSCT for adults with ALL
varies greatly among countries, which may reflect that the
availability of these procedures may be related to economic
issues. However, results of our analysis do not show a clear
correlation between HSCT rates and socioeconomic indices.
Our findings suggest that the use of HSCT may be dependent
on national guidelines, and the observed variation reflects het-
erogeneity of treatment approaches among countries. It should
also be mentioned that the costs of novel drugs and cellular
therapies may exceed the costs of HSCT.
Our study had some limitations, including any assumptions
made regarding ALL incidence for the specified time period
and possible variation in reporting to the EBMT registry from
different countries over time. Despite that, we conclude that
allogeneic HSCT remains a major tool in the fight against
ALL in adults.
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